Literature DB >> 4060968

Serotonergic regulation of prolactin and growth hormone secretion in man.

D A Lewis, B M Sherman.   

Abstract

Controversy still exists regarding the role of serotonin in the regulation of prolactin (Prl) and growth hormone (GH) secretion in man. We gave healthy male volunteers three oral doses (0.5, 1.0 and 1.5 mg/kg) of fenfluramine, a serotonin-releasing agent and uptake inhibitor, and a corresponding placebo. There was a significant dose-response effect of fenfluramine on Prl but not on GH levels. Following the highest dose of fenfluramine, mean Prl levels increased from 9.7 ng/ml to 42.3 ng/ml. In a separate study, subjects were pre-treated with cyproheptadine, a serotonin antagonist, before the administration of fenfluramine. Cyproheptadine did not significantly affect basal Prl or GH levels, but it did blunt the response of Prl to fenfluramine. Cyproheptadine pre-treatment did not alter plasma levels of fenfluramine. Our findings support a stimulatory role for serotonin in the regulation of Prl secretion in man. They also suggest that serotonin does not have a major influence on GH secretion in man.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4060968     DOI: 10.1530/acta.0.1100152

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  7 in total

1.  Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.

Authors:  M Koulu; M Scheinin; A Kaarttinen; J Kallio; K Pyykkö; J Vuorinen; R H Zimmer
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

2.  5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

3.  Effect of fenfluramine on prolactin and thyroid-stimulating-hormone response to thyrotropin-releasing-hormone in obese and normal women.

Authors:  G Argenio; G Bernini; M S Vivaldi; C Del Corso; F Monzani; L Baschieri; G Bertolozzi; R Santoni; F Franchi; M Luisi
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; M Oakes; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

5.  Evidence for 5-hydroxytryptamine1A receptor involvement in the control of prolactin secretion in man.

Authors:  E Palazidou; J Stephenson; J Butler; P Coskeran; S Chambers; A M McGregor
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

6.  Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine.

Authors:  D K Sommers; M van Wyk; J R Snyman
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers.

Authors:  Francis M Dijkstra; Rob G J A Zuiker; Pieter S Siebenga; Richard A Leigh-Pemberton; Lei Sun; Joan D Manthis; Marieke L de Kam; Richard Lin; Lisa L von Moltke; David Rezendes; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2022-01-31       Impact factor: 3.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.